BioNTech will swallow the AI start-up InstaDeep
Like the Mainz pharmaceutical company in a press statement announces that after many years of cooperation with the AI specialist InstaDeep, the complete takeover is now to take place. After being founded in 2014, BioNTech had already invested in the British company in January 2022, but now they apparently want to fully secure the workforce and know-how. The takeover agreement reached includes, among other things, a cash advance payment of around 362 million pounds sterling, the equivalent of almost 410 million euros, as well as other performance-related remuneration.
BioNTech sees the acquisition as an important building block in its strategy to accelerate the development of “next-generation immunotherapies and vaccines” with modern, AI-driven research. 240 highly qualified specialists will also be taken on to strengthen the German company in the areas of AI, bioengineering, data science and software development. You also benefit from the fact that InstaDeep operates several international locations. Karim Beguir, CEO and co-founder of InstaDeep, on the goals they now want to pursue as part of BioNTech: “Together we want to build a world-leading company that combines biopharmaceutical research and artificial intelligence with the aim of delivering next-generation immunotherapies to improve medical care to help fight cancer and other diseases with unmet medical needs.”
Prof. Dr. Sahin, CEO and co-founder of BioNTech, emphasizes that his company’s goal is to integrate AI into everything the company does. In addition to research, this is also of crucial importance in production and sales in order to be able to reach as many patients as possible with new therapies. “Our goal is to make BioNTech a technology company where AI is seamlessly integrated into all aspects of our work,” said Sahin.
